FDA moves closer to new requirements for NTI drugs.
作者信息
Traynor Kate
出版信息
Am J Health Syst Pharm. 2011 Sep 1;68(17):1568-9, 1570. doi: 10.2146/news110059.
PMID:21856797
Abstract
摘要
相似文献
1
FDA moves closer to new requirements for NTI drugs.
Am J Health Syst Pharm. 2011 Sep 1;68(17):1568-9, 1570. doi: 10.2146/news110059.
2
FDA mulls changes to bioequivalence standards.美国食品药品监督管理局考虑修改生物等效性标准。
Am J Health Syst Pharm. 2010 Jun 1;67(11):864. doi: 10.2146/news100040.
3
Multinational medicines--ensuring drug quality in an era of global manufacturing.跨国药品——在全球生产时代确保药品质量。
N Engl J Med. 2009 Aug 20;361(8):737-40. doi: 10.1056/NEJMp0903870.
4
Modeling and simulation of biopharmaceutical performance.生物制药性能的建模与仿真。
Clin Pharmacol Ther. 2014 May;95(5):480-2. doi: 10.1038/clpt.2014.40.
5
Bioavailability and Bioequivalence Aspects of Oral Modified-Release Drug Products.口服缓释制剂的生物利用度和生物等效性方面
AAPS J. 2017 Mar;19(2):360-366. doi: 10.1208/s12248-016-0025-9. Epub 2016 Dec 21.
6
Is Bioequivalence a Sufficient Measure of Equivalence?生物等效性是否是等效性的充分衡量标准？
J Leg Med. 2019 Jul-Sep;39(3):247-261. doi: 10.1080/01947648.2019.1653800.
7
Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.比较仿制药和创新药：对美国食品药品监督管理局12年生物等效性数据的综述
Ann Pharmacother. 2009 Oct;43(10):1583-97. doi: 10.1345/aph.1M141. Epub 2009 Sep 23.
8
Clinical Endpoint Bioequivalence Studies Are Needed: A Perspective From Brand Drugs.需要进行临床终点生物等效性研究：来自品牌药的观点。
Clin Pharmacol Ther. 2019 Feb;105(2):298-300. doi: 10.1002/cpt.1245. Epub 2018 Nov 19.
9
Buy some today: can generics be safely substituted for brand-name drugs?今天就购买：通用名药物能否安全替代品牌药？
Neurology. 2001 Aug 28;57(4):571-3. doi: 10.1212/wnl.57.4.571.
10
Generic equivalence and non-equivalence of drugs.药物的一般等效性与非等效性
Lancet. 1972 Sep 9;2(7776):528-30. doi: 10.1016/s0140-6736(72)91919-8.
Zotero 插件